Alkermes will acquire Avadel Pharmaceuticals for up to $2.1 billion, paying $18.50 cash and a $1.50 CVR per share, adding LUMRYZ and accelerating its sleep medicine market entry.
Kearny Financial shareholders approved the election of five directors, ratified its independent auditor, and endorsed executive compensation at the annual meeting.
City Holding reported record Q3 net income of $35.2 million and diluted EPS of $2.41, driven by robust loan growth and higher net interest income.
Fidelity D&D Bancorp reported a 48% surge in Q3 net income to $7.3 million, with diluted EPS of $1.27, driven by strong net interest income growth.
Armata Pharmaceuticals reported positive Phase 2a results for its AP-SA02 therapy in treating complicated Staphylococcus aureus bacteremia, showing higher cure rates and no relapses.
Super League Enterprise completed a $15.25 million private placement, issued various warrants, amended its charter, and held its annual stockholder meeting.